Pioneering license agreement with BrainTransporter signed with BMS worth up to USD 1.35 billion plus royalties Events during the fourth quarter 2024 The Australian Medicines Agency (TGA) decided not ...

Imagine you have just been diagnosed with mild cognitive decline due to Alzheimer’s disease. Your doctor might suggest taking ...

Q4 2024 Earnings Call Transcript February 12, 2025 Operator: Good morning. My name is Jennifer and I will be your conference ...

Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Biogen (BIIB) to $157 from $192 and keeps an Equal Weight rating on the ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Royalty Pharma has signed a deal to pay Biogen $250m to support the development of its late-stage experimental lupus ...

Biogen Inc (BIIB) reports a 17% increase in Q4 EPS, driven by new product launches, despite facing revenue declines and competitive pressures.

We think Biogen's neurology, immunology, and focus on rare diseases support a narrow moat. Biogen's strategy has its roots in the 2003 merger of Biogen (Avonex for treating multiple sclerosis, or MS) ...

Biogen beat Q4 estimates with a 17% EPS rise and $2.46 billion in sales. The company expects revenue declines in 2025 as multiple sclerosis drug sales drop.

Research supporting the amyloid hypothesis—the idea that Alzheimer's is caused by a buildup of amyloid plaques in the ...

Royalty Pharma is giving Biogen $250 million for its lupus treatment litifilimab, which is currently in Phase 3 development ...